Bank of America’s latest four-week scanner data through May 30 showed continued volume declines across most U.S. tobacco categories, while oral nicotine products remained the industry’s strongest growth segment, according to Investing.com. It said industry cigarette sales fell 3.3%, with volumes down 7.4%, while vapor sales declined 17.2%. In contrast, oral tobacco sales increased 5.8%, driven by a 0.4% rise in volume and a 5.4% improvement in price mix.
Among major manufacturers mentioned in the article, British American Tobacco delivered the strongest oral nicotine performance, with sales up 28.3% and share gains of 590 basis points, while vapor sales increased 8.8%. Altria gained 20 basis points of cigarette share despite a 6.9% volume decline, but continued to lose share in vapor and oral products. Philip Morris International reported modest 0.6% growth in oral tobacco sales ahead of the U.S. rollout of Zyn Ultra, while Imperial Brands posted 34.6% growth in smokeless and oral products. Japan Tobacco was the only major manufacturer to record cigarette volume growth, with cigarette sales rising 2.6% and share increasing by 70 basis points.